Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia (Bortezomib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01328236
Recruitment Status : Unknown
Verified September 2011 by wangzhao, Clinical Service, China.
Recruitment status was:  Recruiting
First Posted : April 4, 2011
Last Update Posted : September 22, 2011
Harbin Hematology and Oncology Institute
Shanghai Changzheng Hospital
Chinese PLA General Hospital
307 Hospital of PLA
Wuhan Union Hospital, China
Beijing Chao Yang Hospital
Henan Provincial Hospital
Peking University Third Hospital
Information provided by (Responsible Party):
wangzhao, Clinical Service, China

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : September 2013
  Estimated Study Completion Date : September 2015